Key result
A survey of 55 Portuguese heart failure specialists revealed selective use of digitalis glycosides primarily for rate control and symptom relief after optimizing foundational therapies.
Why the study?
Digitalis glycosides are among the oldest therapies for heart failure with reduced ejection fraction, yet their contemporary role remains debated.
Current data and expert consensus support repositioning digitalis as a low-dose, concentration-guided neurohormonal modulator and rate-control agent for carefully selected HFrEF patients.
No takes yet. Share an insight, caveat, or question.
Supports selective digitalis use for rate control in optimized HFrEF; leaves open need for RCTs on outcomes.
Gonçalves et al. (2026) conducted a review in Heart failure with reduced ejection fraction (n=55). Digitalis glycosides was evaluated. A survey of 55 Portuguese heart failure specialists revealed selective use of digitalis glycosides primarily for rate control and symptom relief after optimizing foundational therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: